alexa Exploiting Unique Interactions In The MKK3/6 And ASK1 Kinase Active Sites Through Computer- Aided Drug Design
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th International Conference on Medicinal Chemistry & Computer Aided Drug Designing and Drug Delivery
December 05-07, 2016 Phoenix, USA

Simone Verene Bigi
Takeda California, Inc., USA
ScientificTracks Abstracts: Med chem
DOI: 10.4172/2161-0444.C1.027
Since the early 1990’s, the concept of structure-based drug design has been demonstrated on a wide array of protein targets, becoming an established and integral part of drug discovery and lead optimization. While now synonymous with this concept, computer-aided modeling is widely recognized as a seminal aspect of structurally enabled drug discovery programs. The ubiquitous exposure to structural information has spawned a scientific enlightenment around the details and nuances of protein structural information. Kinases are one of the most extensively studied protein families based on the vast number of structures currently available in the Protein Data Bank. Although they share similar architectures and substrates, it is still quite common to identify unique interactions within these proteins that can yield highly selective inhibitors. My talk will describe the use of computer-aided drug design in the context of optimizing novel inhibitors of the two kinases: MAP Kinase Kinase isoforms 3/6 (MKK3/6) and the Apoptosis Signal-Regulating Kinase 1 (ASK1). Each of these kinases is found within the MAPK pathway and contain unique residues and interactions in the active site. Using structure-based modeling, these differences were exploited to enhance inhibitor potency and selectivity. These efforts yielded highly efficient and selective tool compounds that were valuable in testing key pharmacological hypotheses in the areas of immunological and cardiovascular diseases.

Simone Verene Bigi completed her BS from University of Notre Dame in South Bend, Indiana.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version